ArticleCureus2025
Oral Cephalosporin-Induced Anaphylaxis Presenting With Severe Tachycardia: A Case of Microdosed Epinephrine Over Standard Protocols.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a severe, rapidly progressing hypersensitivity reaction that requires prompt recognition and administration of intramuscular epinephrine. While guidelines recommend fixed-dose intramuscular epinephrine regardless of heart rate or blood pressure, there are situations where this approach may carry risks. We present the case of a 27-year-old patient with no prior comorbidities, including asthma, allergies, or cardiovascular conditions, who developed sudden breathlessness, generalized urticaria, and swelling of the face and lips shortly after taking oral cefpodoxime, a third-generation cephalosporin, prescribed for a febrile illness at a local hospital. On arrival at our hospital, the patient was conscious and alert, with an oxygen saturation of 87% on room air, a heart rate of 169 beats per minute, and a blood pressure of 100/60 mmHg. The ABCDE (Airway, Breathing, Circulation, Disability, Exposure) protocol was followed, and supportive care including oxygen, nebulized bronchodilators, and intravenous fluids was provided. Given the clear signs of anaphylaxis with marked tachycardia but no hypotension, there was a dilemma regarding the administration of standard intramuscular epinephrine due to concerns about worsening tachyarrhythmias. Under close monitoring, carefully titrated microdosed intravenous epinephrine was administered using a dilution protocol, resulting in rapid symptom improvement without cardiovascular instability. The patient was admitted to the intensive care unit for monitoring and supportive care and was later discharged in stable condition with oral antihistamines, corticosteroids, and clear instructions on allergen avoidance to prevent future emergencies. This case illustrates the need for clinical judgment when strict adherence to guidelines may pose a risk and demonstrates the role of individualized microdosed intravenous epinephrine in managing anaphylaxis in patients with significant tachycardia and normotension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.